The present invention relates to pharmaceutical compositions in
particulate form or in solid dosage forms comprising a combination of
fenofibrate and the HMG CoA reductase inhibitor rosuvastatin or a
pharmaceutically active salt thereof, which upon oral administration
provides a relative AUC.sub.0-24 value (AUC.sub.fibric
acid/AUC.sub.rosuvastatin) of between about 150 and about 12,000. The
solid compositions are manufactured without any need of addition of water
or aqueous medium and comprise at least 80% of the active substances
fenofibrate and rosuvastatin in dissolved form, or, optionally,
atorvastatin in micronized form, in order to ensure suitable
bioavailability.
